mao a

MAO A/HDAC-IN-1 is an effective dual inhibitor of monoamine oxidase A (MAO A) and HDAC, suitable for glioma research.

MAO A/HSP90-IN-1 (4-b) is a dual inhibitor of MAO A and HSP90, with IC50 values of 1.77 μM in glioblastoma (GBM) GL26 cells and 0.019 μM against HSP90α. This compound impairs MAO A activity, disrupts HSP90 binding, and downregulates HER2 and phospho-Akt expressions, thus inhibiting GBM growth. Additionally, it reduces PD-L1 expression, thwarting T cell activation and potential tumor immune evasion. MAO A/HSP90-IN-1 (4-b) is valuable for research into brain tumor-related diseases [1].

MAO A/HSP90-IN-2 (compound 4-C), a dual inhibitor of HSP90 and MAO A, exhibits IC50 values of 0.016 μM for MAO A and 4.58 μM for HSP90. This compound enhances HSP70 expression, diminishes HER2 and phospho-Akt levels, downregulates IFN-γ-induced PD-L1 expression in GL26 cells, and demonstrates efficacy against Temozolomide-sensitive and -resistant GBM cells, colon cancer, leukemia, and non-small cell lung cancer, possibly impeding tumor immune evasion [1].

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), also inhibiting microglial production of neuroinflammatory mediators. This compound is specifically designed for research on neurodegenerative diseases [1].

MAO-B-IN-30 is a selective and potent MAO-B inhibitor that crosses the blood-brain barrier with antiproliferative activity and inhibits both MAO-A and MAO-B.MAO-B-IN-30 reduces the levels of TNF-alpha, IL-6, and NF-kB in organisms, and can be used to study Parkinson's-type neurological disorders.

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

MAO-A/SERT-IN-1 acts as an inhibitor for both MAO-A and the serotonin transporter (SERT). It decreases the SERT-mediated reuptake of 5-HT and demonstrates neuroprotective properties in cellular inhibition models. Additionally, this compound has shown to alleviate depressive behaviors in both zebrafish and mice.

MAO-B-IN-37 (Compound 37) is a derivative of TT01001 and acts as a selective inhibitor of monoamine oxidase B (MAO-B), with an IC50 of 270 nM. It exhibits good metabolic stability in mouse microsomes and shows strong affinity for human serum albumin.

MAO-A inhibitor3 (Compound 360) is an MAO-A inhibitor with an IC50 greater than 100 μM. It is utilized in the investigation of neurological disorders.

MAO-B-IN-39 (compound11) is a potent inhibitor of monoamine oxidase B (MAO-B), with an IC50 of 3.61 μM. It demonstrates strong NRF2 induction capabilities and exhibits significant anti-inflammatory and neuroprotective effects in oxidative stress-related in vitro models. Additionally, MAO-B-IN-39 shows high liver microsomal stability and favorable pharmacokinetic properties in mice, making it a valuable compound for Parkinson's disease research.

MAO-B-IN-43 (4) is a potent inhibitor of hMAO-B and a mild inhibitor of GSK3β kinase, with Ki values for hMAO-A and hMAO-B of 0.044 μM and 0.004 μM, respectively. This compound is applicable in the study of neurodegenerative diseases.

MAO-A inhibitor2 (compound HT4) is a monoamine oxidase A (MAO-A) inhibitor with an IC50 of 14.3 µM. It exhibits minimal impact on MAO-B (IC50 of 106 µM) and is almost ineffective against xanthine oxidase (XO). MAO-A inhibitor2 is applicable in research on neurodegenerative diseases and oxidative stress.

MAO-B-IN-44 (Compound 4n) is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.01 μM, demonstrating weak inhibition of MAO-A (IC50=14.4 μM). It reduces the degradation of neurotransmitters like dopamine and holds potential for research into neurodegenerative diseases such as Parkinson's disease, which are associated with MAO-B abnormalities.

MAO-A-IN-2 (Compound 4l) is a selective inhibitor of monoamine oxidase A (MAO-A) with an IC50 value of 0.4 μM. This compound reduces the degradation of monoamine neurotransmitters, such as serotonin and norepinephrine. MAO-A-IN-2 holds potential for research in neurological disorders related to monoamine neurotransmitter imbalance, including depression and anxiety.

MAO-B-IN-46 (Compound 16) is a selective human MAO-B inhibitor with an IC50 of 26.8 nM, while showing weaker activity against hMAO-A (IC50: 7.2054 μM). This compound, also referred to as MAO-B-IN-46 (Compound 8), acts as an α-amylase inhibitor with an IC50 of 19.46 μM. It demonstrates certain neuroprotective properties and exhibits no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS radicals, with IC50 values of 17.86 and 17.71 μM, respectively. MAO-B-IN-46 is applicable in research on neurodegenerative diseases like Parkinson's, diabetes, and conditions related to oxidative stress.

MAO-IN-M30 dihydrochloride is a highly potent non-selective inhibitor of MAO-A and MAO-B (IC50 < 0.1 μM). MAO-IN-M30 dihydrochloride is orally active and can cross the blood-brain barrier. It is an effective iron chelator and free radical scavenger. MAO-IN-M30 dihydrochloride has neuroprotective activity in in vitro and in vivo models of Parkinson's disease (PD). It increases brain dopamine, serotonin and norepinephrine and can serve as a lead drug for the development of multifunctional drugs to treat various neurodegenerative diseases.

MAO-B-IN-15 is a selective MAO-B inhibitor (IC50 = 13.5 μM) that forms π-π interactions with the Tyr 326 residue, and it can be utilized in Parkinson's disease research[1].

MAO-B-IN-16 is a selective inhibitor of monoamine oxidase B (MAO-B) with an IC50 of 1.55 μM, suitable for research in central nervous system disorders such as Parkinson's disease [1].

MAO-B-IN-17 is a selective and potent monoamine oxidase B (MAO-B) inhibitor (IC50: 5.08 μM) used in the study of central nervous system disorders, including Parkinson's.

MAO-B-IN-10 (compound 4f) is a highly potent and selective MAO-B (monoamine oxidase-B) inhibitor that effectively penetrates the blood-brain barrier, exhibiting an IC50 of 5.3 μM. It demonstrates the ability to inhibit self-mediated Aβ (amyloid β) aggregation by 58.2% and disaggregate it by 43.3%, holding promise for Alzheimer's disease research [1].

MAO-B-IN-6 is a selective, potent, orally active MAO-B inhibitor (IC50: 0.019 μM) and demonstrates superior efficacy to Safinamide both in vitro and in vivo.

MAO-B ligand-1 is a selective MAO-B inhibitor.

AChE/MAO-IN-1 is a potent inhibitor of human acetylcholinesterase (AChE), monoamine oxidase A (MAO-A), and monoamine oxidase B (MAO-B), demonstrating inhibitory concentrations (IC50) of 0.0248 μM, 0.0409 μM, and 0.1108 μM against AChE, MAO-A, and MAO-B, respectively.

Dual AChE-MAO B-IN-5, an indanone derivative, serves as an effective dual inhibitor for AChE and MAO-B, displaying IC50 values of 0.0224 μM for AChE, 0.0412 μM for MAO-B, and 0.1116 μM for MAO-A. Additionally, it exhibits antioxidant properties and inhibits β-amyloid plaque aggregation, making it suitable for Alzheimer's disease (AD) research.